Clinical trials: Tissue Damage
Cartilage Damage
Advanced Cartilage Treatment With Injectable-hydrogel Validation of the Effect
Multicentre, pivotal, non-randomized, prospective, open-label clinical investigation involving a new hydrogel, Hy2Care Injectable hydrogel, developed by Hy2Care B.V., Enschede, The Netherlands (hereafter referred to as "Hy2Care")…
- Trial name
- ACTIVE (NCT05186935)
- Testing
- Injectable Hydrogel treatment
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Hy2Care BV
Rheumatoid Arthritis
A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
An open ended study in which patients who completed the preceding double-blind study NCT00160602 are given Certolizumab Pegol and assessed for signs and symptoms of Rheumatoid Arthritis.
- Trial name
- NCT00160641
- Testing
- Certolizumab Pegol
- Where
- 67 sites in United States, Bulgaria and 11 more
- Volunteers
- 567 people
- Sponsor
- UCB Pharma
Musculoskeletal Inflammation, Exercise-Induced Muscle Damage
A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery
This study will evaluate the effects of Parlay Recover peptide gummies (containing Body Protection Compound BPC-157) on markers of inflammation, physical performance, and recovery in physically active adults.
- Conditions
- Musculoskeletal Inflammation, Exercise-Induced Muscle Damage, Post-Exercise Recovery, Musculoskeletal Pain
- Trial name
- NCT07752381
- Testing
- Parlay Recover Peptide Gummies
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Parlay Wellness
Neovascular Age-related Macular Degeneration
Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD
AMD (Age Related Macular Degeneration) is the leading cause of severe visual loss and blindness registration in the UK . It is a disease which affects the retina (the nerve and blood vessel network at the back of the eye…
- Trial name
- SAFARI (NCT02161575)
- Testing
- Ranibizumab
- Where
- 28 sites in Germany, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Osteoarthritis, Knee Pain Arthritis
Long-Term Study of CartiPRO for Knee Pain Due to Osteoarthritis or Cartilage Damage
This clinical trial aims to evaluate and compare the efficacy and safety of CartiPRO, an approved intra-articular atelocollagen injection, versus Synovian injection for the relief of knee pain in patients with knee…
- Conditions
- Osteoarthritis, Knee Pain Arthritis, Cartilage Defects of the Knee, Knee Osteoarthritis
- Trial name
- NCT07267793
- Testing
- CartiPRO, Synovian®
- Where
- 5 sites in South Korea
- Volunteers
- 194 people
- Sponsor
- DALIM TISSEN Co., Ltd.
Acute Myocardial Infarction
PROTECT : Pacing to Protect Heart for Damage From Blocked Heart Vessel and From Re-opening Blocked Vessel(s)
To determine whether the application of ventricular pacing can protect the human heart from damage resulting from a myocardial infarction
- Trial name
- NCT00409604
- Testing
- Temporary RV VVI pacing
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Guidant Corporation
Pea Proteins, Muscle Damage
Effects of Pea Proteins on Muscle Damage and Recovery
This study is a double-blind, randomized, placebo-controlled, crossover clinical trial of N=40 recreationally active men to be recruited a single investigational center in Ohio (i.e., The Center for Applied Health Sciences).
- Conditions
- Pea Proteins, Muscle Damage, Amino Acid Change
- Trial name
- NCT05657314
- Testing
- Active Comparator
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The Center for Applied Health Sciences, LLC
Spondylitis, Ankylosing
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs
This randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with ankylosing spondylitis (AS) who have failed treatment with non-steroidal…
- Trial name
- NCT01209702
- Testing
- tocilizumab
- Where
- 139 sites in United States, Australia and 16 more
- Volunteers
- 306 people
- Sponsor
- Hoffmann-La Roche
Acute Respiratory Distress Syndrome
Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome)
The primary object of this clinical study is to investigate the efficacy and the safety of NOA-001 in patients with ARDS (ARDS caused by Non-COVID-19 or COVID-19).
- Trial name
- NCT04804943
- Testing
- NOA-001
- Where
- Japan
- Volunteers
- 45 people
- Sponsor
- Toray Industries, Inc
Cerebral Palsy, Dyskinetic
A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
CP (cerebral palsy) refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement and muscle coordination.
- Trial name
- RECLAIM-DCP (NCT03813238)
- Testing
- TEV-50717
- Where
- 70 sites in United States, Belgium and 10 more
- Volunteers
- 63 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Percutaneous Coronary Intervention
Pitavastatin Pre-Treatment Study in Patient With Elective PCI for Stable Angina Pectoris (PIPA)
Patients who is scheduled elective PCI are randomized to pitavastatin 4mg daily or without pitavastatin for 5 -7days before the procedure.
- Trial name
- NCT00786734
- Testing
- Pitavastatin
- Where
- South Korea
- Sponsor
- JW Pharmaceutical
Soreness, Muscle, Performance Enhancing Product Use
Acute Study on Muscle Soreness, Damage, and Performance
The acute study will evaluate pre- and post-exercise ingestion of a multi-ingredient supplement in a randomized, double-blind, placebo-controlled, crossover design.
- Conditions
- Soreness, Muscle, Performance Enhancing Product Use, Damage Muscle
- Trial name
- NCT04230226
- Testing
- Pre-workout plus and protein recovery plus
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pharmanex
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
This is a modular, phase I/ phase 1 b, open-label, multicentre study of ceralasertib administered orally in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to patients with advanced malignancies.
- Trial name
- NCT02264678
- Testing
- Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab
- Where
- 28 sites in United States, France and 2 more
- Volunteers
- 358 people
- Sponsor
- AstraZeneca
Disorders of Consciousness, Vegetative State
AI-Assisted Precision Hyperbaric Oxygen Therapy Based on Dynamic BIS-EEG Feedback for Patients With Disorders of Consciousness
Disorders of consciousness (DoC) are severe neurological conditions characterized by impaired awareness and reduced interaction with the environment.
- Conditions
- Disorders of Consciousness, Vegetative State, Minimally Conscious State
- Trial name
- AI-HBOT-DoC (NCT07855848)
- Testing
- AI-Assisted Personalized Hyperbaric Oxygen Therapy, Conventional Hyperbaric Oxygen Therapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Systemic Lupus Erythematosus
Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis
This is a multicenter prospective study to assess clinical characteristics, demographics, treatment and health-related quality of life (HRQoL) of lupus nephritis (LN) participants across 5 Gulf countries (United Arab Emirates…
- Trial name
- NCT04971590
- Testing
- Participant completed survey, Medical chart review
- Where
- 6 sites in Kuwait, Oman and 2 more
- Volunteers
- 193 people
- Sponsor
- GlaxoSmithKline
Muscle Spasticity, Hypertonia, Muscle
Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals
To assess the safety and tolerability of single and multiple doses of MTR-601 in normal healthy volunteers under fed and fasted conditions. To evaluate the plasma and urine pharmacokinetics (PK) of MTR-601.
- Conditions
- Muscle Spasticity, Hypertonia, Muscle, Cerebral Palsy, Multiple Sclerosis
- Trial name
- NCT06117020
- Testing
- MTR-601
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Motric Bio
Cerebral Palsy (CP)
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A double-blind, placebo-controlled, crossover study in subjects with cerebral palsy (CP) to evaluate the safety and tolerability and the effect of dalfampridine extended release (ER) tablets on sensorimotor function
- Trial name
- NCT01468350
- Testing
- dalfampridine-ER 10mg
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Acorda Therapeutics
Tendon Injuries
A Methodology Study to Assess Muscle Damage After Eccentric Exercise
An isolated bout of unaccustomed maximal eccentric exercise is associated with muscle force loss for 2-4 days, mild reversible muscle tenderness, and ultra-structural damage to the muscle fibers, elevation of muscle proteins in…
- Trial name
- NCT02014662
- Testing
- Eccentric exercise
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Skin Abnormalities
Evaluation of Effects of HP828-101 for Moisture Associated Skin Damage
This study evaluates HP828 in the management of moisture associated skin damage after 15 days of use.
- Trial name
- NCT01108523
- Testing
- HP828-101
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Healthpoint
Sialorrhea
Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults
Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea.
- Trial name
- OPTIMYST (NCT02610868)
- Testing
- MYOBLOC
- Where
- 35 sites in United States, Belarus and 1 more
- Volunteers
- 187 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC